The Technical Analyst
TELA Bio Inc [TELA]
Exchange: NASDAQ Sector: Healthcare Industry: Medical Devices
TELA Bio Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-2.19% $4.47
America/New_York / 23 apr 2024 @ 11:04
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 110.20 mill |
| EPS: | -2.04 |
| P/E: | -2.19 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 24.65 mill |
| Avg Daily Volume: | 0.125 mill |
| RATING 2024-04-22 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Strong Buy | |
| P/E: | Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -2.19 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.01x |
| Company: PE -2.19 | industry: PE 222.16 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 4.18 - 4.82 ( +/- 7.02%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-31 | Firestone Gregory A. | Sell | 119 | Common Stock |
| 2024-03-31 | Koblish Antony | Sell | 385 | Common Stock |
| 2024-03-31 | Talmo Paul | Sell | 190 | Common Stock |
| 2024-03-31 | Smeykal Megan | Sell | 96 | Common Stock |
| 2024-03-31 | Murphy Peter C. | Sell | 163 | Common Stock |
| INSIDER POWER |
|---|
| 54.56 |
| Last 99 transactions |
| Buy: 1 093 142 | Sell: 280 600 |
Forecast:
12:43 - $4.55
Live Trading Signals (every 1 min)
Forecast
1: 11:13 - $4.46
Forecast 2: 12:03 - $4.57
Forecast 3: 12:43 - $4.55
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $4.47 (-2.19% ) |
| Volume | 0.0240 mill |
| Avg. Vol. | 0.125 mill |
| % of Avg. Vol | 19.19 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For TELA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $6.86 | N/A | Active |
|---|
TELA
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Latest Press Releases
2024-04-15 07:00:00 - Press Release
Tela Bio Announces U.s. Commercial Launch Of Robotic-compatible Ovitex® Ihr – Addressing The Need For A More Natural Repair In Inguinal Hernia Procedures
Targets the more than 665,000 inguinal hernia procedures performed annually in the united states (u.s.) targets the more than 665,000 inguinal hernia procedures performed annually in the united states (u.s.)
2024-04-08 07:00:00 - Press Release
Tela Bio Welcomes Acclaimed Surgeon As Vice President Of Medical Affairs And Surgeon Strategy
Howard n. langstein, md, facs joins innovative medtech company to leverage his vast experience to help other surgeons optimize clinical outcomes in plastic and reconstructive surgery howard n. langstein, md, facs joins innovative medtech company to leverage his vast experience to help other surgeons optimize clinical outcomes in plastic and reconstructive surgery
2024-03-21 16:05:00 - Press Release
Tela Bio Achieves Record Fourth Quarter And Full Year 2023 Revenues And Reports Complete Financial Results
Malvern, pa., march 21, 2024 (globe newswire) -- tela bio, inc. ("tela bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today reported financial results for the fourth quarter and full year ended december 31, 2023.
2024-03-21 07:00:00 - Press Release
Tela Bio Announces U.s. Commercial Launch Of Liquifix™ – The Only Fda-approved Liquid Adhesive For Internal Use In Hernia Surgery
Strong and secure, liquifix is the first approved adhesive-based product to affix mesh without penetrating patient tissue strong and secure, liquifix is the first approved adhesive-based product to affix mesh without penetrating patient tissue
2024-03-20 07:00:00 - Press Release
Tela Bio Announces Sale Of Distribution Rights For Wound Care Product To Mimedx
Tela bio to receive at least $8 million and up to $12 million in total consideration tela bio to receive at least $8 million and up to $12 million in total consideration
Latest News
2024-03-21 19:38:03 - Seeking Alpha
TELA Bio, Inc. (TELA) Q4 2023 Earnings Call Transcript
2024-03-21 18:31:03 - Zacks Investment Research
TELA Bio, Inc. (TELA) Reports Q4 Loss, Tops Revenue Estimates
TELA Bio, Inc. (TELA) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.52 per share a year ago.
2024-02-29 07:00:00 - GlobeNewsWire
TELA Bio to Announce Fourth Quarter and Full Year 2023 Financial Results
MALVERN, Pa., Feb. 29, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today announced that the Company will report fourth quarter and full year 2023 financial results on Thursday, March 21, 2024. TELA Bio's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.
2024-01-16 02:34:33 - Seeking Alpha
TELA Bio: Looks Like A Buy, But Some Pieces Missing To Make This A Strong Buy
OviTex sales continue to see strong annual growth. However, before being able to conclusively say that OviTex is better than competitors, some head-to-head data is needed. The liquidity position is not great, and dilution seems likely.
2023-11-12 01:42:04 - Seeking Alpha
TELA Bio, Inc. (TELA) Q3 2023 Earnings Call Transcript
TELA Bio, Inc. (NASDAQ:TELA ) Q3 2023 Earnings Call Transcript November 9, 2023 4:30 PM ET Company Participants Greg Chodaczek - Gilmartin Group Tony Koblish - President and Chief Executive Officer Roberto Cuca - Chief Operating Officer and Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Caitlin Cronin - Canaccord Genuity Matthew O'Brien - Piper Sandler Michael Sarcone - Jefferies Dave Turkaly - JMP Securities Operator Good day and thank you for standing by, and welcome to the TELA Bio Third Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode.
2023-10-26 07:00:00 - GlobeNewsWire
TELA Bio to Announce Third Quarter 2023 Financial Results
MALVERN, Pa., Oct. 26, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today announced that the Company will report third quarter 2023 financial results on Thursday, November 9, 2023. TELA Bio's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.
2023-08-09 19:44:08 - Zacks Investment Research
TELA Bio, Inc. (TELA) Reports Q2 Loss, Lags Revenue Estimates
TELA Bio, Inc. (TELA) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.58. This compares to loss of $0.80 per share a year ago.
2023-07-26 07:00:00 - GlobeNewsWire
TELA Bio to Announce Second Quarter 2023 Financial Results and Confirms Participation in the Canaccord Genuity 43rd Annual Growth Conference
MALVERN, Pa., July 26, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today announced that the Company will report second quarter 2023 financial results on Wednesday, August 9, 2023. TELA Bio's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.
2023-06-19 02:42:04 - Zacks Investment Research
Strength Seen in TELA Bio, Inc. (TELA): Can Its 11.4% Jump Turn into More Strength?
TELA Bio, Inc. (TELA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
2023-05-25 07:00:00 - GlobeNewsWire
TELA Bio to Participate in the Jefferies Global Healthcare Conference
MALVERN, Pa., May 25, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today announced that the Company will participate in the Jefferies Global Healthcare Conference on Wednesday, June 7th, 2023.